Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

APA Update: New Antidepressants Elbow Into Crowded Market

Executive Summary

Lundbeck/Takeda unveil pivotal trial data for Brintellix (vortioxetine) in major depression, while Forest pooled analyses shed more light on levomilnacipran in subgroups. Docs don’t think the new drugs are differentiated, but since antidepressant response is so quirky, the prescribing door is still open.

Advertisement

Related Content

BIO 2014 Tuesday Round-Up: AstraZeneca Looking Forward, Not Back
Additional Cariprazine Trial Could Put Forest In A Better Competitive Position
Lilly’s Late-Stage CNS Pipeline Bare Following Edivoxetine Failure
More Me-Too Drugs Please, FDA’s Jenkins Asks Industry
Lilly’s Late-Stage CNS Pipeline Bare Following Edivoxetine Failure
Additional Cariprazine Trial Could Put Forest In A Better Competitive Position
Many New Products For Forest, But Not Enough To Fill The Lexapro Gap
Forest Builds On Viibryd With Levomilnacipran NDA For Its “Middle” Antidepressant
On A Revenue Roll, Shire Takes Specialist Tactics To “Primary Care” Markets
MDD Market Snapshot: Depressing Future For Antidepressants

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055364

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel